 |
|
|
| |
Daclatasvir and Asunaprevir in Non-Japanese Asian Patients with Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies with or without Ribavirin: Phase 3 SVR12 Interim Results
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Wei L,1 Zhang MX,2 Xu M,3 Chuang WL,4 Lu W,5 Xie W,6 Jia ZS,7 Gong GZ,8 Li YQ,9 Bae SH,10 Yang YF,11 Xie Q,12 Lin SM,13 Chen XY,14 Niu JQ,15 Jia JD,16 Garimella T,17 Torbeyns A,18 McPhee F,19 Treitel M,17 Yin PD,19 Mo L20
1Peking University People's Hospital and Peking University Hepatology Institute, Beijing, China; 2The Sixth People's Hospital of Shenyang, Shenyang, China; 3Guangzhou No.8 People's Hospital, Guangzhou, China; 4Kaohsiung Medical University, Kaohsiung, Taiwan; 5Tianjin Second People's Hospital, Tianjin, China; 6Beijing Ditan Hospital, Capital Medical University, Beijing, China; 7Tangdu Hospital, Tangdu, China; 8The Second Xiangya Hospital of Central South University, Xiangya, China; 9302 Military Hospital of China, Beijing, China; 10Seoul St. Mary Hospital, The Catholic University of Korea, Seoul, Korea; 11The 2nd Hospital of Nanjing, Affiliated to Medical School of South East University, Nanjing, China; 12Shanghai Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China; 13The First Affiliated Hospital of Xi'an Jiaotong University, Jiaotong, China; 14Beijing Youan Hospital, Capital Medical University, Beijing, China; 15First Hospital of Jilin University, Jilin, China; 16Beijing Friendship Hospital, Capital Medical University, Beijing, China; 17Bristol-Myers Squibb, Princeton, NJ, US; 18Bristol-Myers Squibb, Braine-l'Alleud, Belgium; 19Bristol-Myers Squibb, Wallingford, CT, US; 20Bristol-Myers Squibb, Shanghai, China
|
| |
|
|
|
|
|
